Glitazone use associated with reduced risk of Parkinson's disease.

Brage BrakedalIrene FlønesSimone F ReiterØivind TorkildsenChristian DölleJörg AssmusKristoffer Haugarvoll Charalampos Tzoulis

Published in: Movement disorders : official journal of the Movement Disorder Society (2017)

The use of glitazones is associated with a decreased risk of incident PD in populations with diabetes. Further studies are warranted to confirm and understand the role of glitazones in neurodegeneration. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

Keyphrases

cardiovascular disease
type diabetes
glycemic control
case control
randomized controlled trial
genetic diversity
metabolic syndrome
meta analyses
insulin resistance
weight loss